Abstract
Treatment of children with steroid-dependent nephrotic syndrome (SDNS) continues to be a challenge when relapses recur after treatment with cyclophosphamide and side effects or non-compliance make steroids and cyclosporin unsatisfactory. We treated 12 patients with intravenous vincristine for SDNS in a regime of 1–1.5 mg/m2 weekly for 4 weeks then monthly for 4 months. Four of the 5 patients in relapse when commencing vincristine remitted within 2 doses. Comparing relapse frequency in the 12 months before and after vincristine, there was a reduction from 4 to 1.5 (p=0.004) relapses per year. Median sustained remission was 5 months, but 1 frequently relapsing patient remains in remission 4 years after vincristine. Vincristine was also successfully used in 1 or 2 doses at weekly intervals for subsequent relapses in 5 patients. Side effects were minimal in most cases. Abdominal pain occurred in 2 patients who commenced vincristine at 1.5 mg/m2, but resolved when continued at 1 mg/m2. We felt vincristine had a role in a subset of children with challenging SDNS administered as 1 mg/m2 weekly for 4 weeks then 1.5 mg/m2 monthly for 4 months. Vincristine allowed steroid- and cyclosporin-sparing, contributed to long-term remission in some patients, and was especially valuable in children with poor compliance with oral medication. Many patients expressed a preference for a few doses of vincristine rather than a standard course of oral prednisolone or cyclosporin.
We’re sorry, something doesn't seem to be working properly.
Please try refreshing the page. If that doesn't work, please contact support so we can address the problem.
References
Honda M (2002) Nephrotic syndrome and mizoribine in children. Pediatr Int 44:21–216
Sharma RK, Sahu KM, Gulati S, Gupta A (2000) Pefloxacin in steroid dependent and resistant idopathic nephrotic syndrome. J Nephrol 13:271–274
Chandra M, Susin M, Abitbol C (2000) Remission of relapsing childhood nephrotic syndrome with mycophenolate mofetile. Pediatr Nephrol 14:224–226
Alsaran K, Grisaru S, Stephens D, Arbus G (2001) Levamisole vs. cyclophosphamide for frequently-relapsing steroid-dependent nephrotic syndrome. Clin Nephrol 56(4):289–294
Donia AF, Amer GM, Ahmed HA, Gazareen SH, Moustafa FE, Shoeib AA, Ismail AM, Khamis S, Sobh MA (2002) Levamisole: adjunctive therapy in steroid dependent minimal change nephrotic children. Pediatr Nephrol 17:355–358
Goonsekera CDA, Koziell AB, Hulton SA, Dillon MJ (1998) Vincristine and focal segmental sclerosis: do we need a multicentre trial? Pediar Nephrol 12:284–289
Almeida MP, Almeida HA, Coelho Rosa F (1994) Vincristine in steroid-resistant nephrotic syndrome. Pediar Nephrol 8:79–80
Almeida M, Ribeiro M, Rosa FC (1987) Effect of vincristine in corticoresistant nephrotic syndrome. Pediatr Nephrol 1:C93 (abstract)
Schwartz GJ, Haycock GB, Edelman, CM, Spitzer A (1976). A simple estimate of glomerular filtration rate in children derived from body length and plasma creatinine. Pediatrics 58:259–263
StataCorp (2003) Stat Statistical Software: Release 8.0. Stata Corporation, College Station, TX
Vilpo JA, Koski T, Vilpo LM (2000) Selective toxicity of vincristine against chronic lymphocytic leukemia cell in vitro. Eur J Haematol 65:370–378
Kubosawa H, Kondo Y (1994) Modulation of cytoskeletal organization of podocytes during the course of aminonucleoside nephrosis in rats. Pathol Int 44(8):578–586
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Kausman, J.Y., Yin, L., Jones, C.L. et al. Vincristine treatment in steroid-dependent nephrotic syndrome. Pediatr Nephrol 20, 1416–1419 (2005). https://doi.org/10.1007/s00467-005-1940-7
Received:
Revised:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00467-005-1940-7